Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Abstract: Systemic inflammation is a key risk factor for hepatocellular carcinoma (HCC) progression and poor outcomes. Inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) may have prognostic value in HCC treated with standard of care atezolizumab plus bevacizumab (Atezo-Bev). We conducted a multicenter, international retrospective cohort study of patients with unresectable HCC treated with Atezo-Bev to assess the association of NLR and PLR with overall survival (OS), progression-free survival (PFS), and objective response rates. Patients with NLR ≥ 5 had a significantly shorter OS (9.38 vs. 16.79 months, p < 0.001) and PFS (4.90 vs. 7.58 months, p = 0.03) compared to patients with NLR < 5. NLR ≥ 5 was an independent prognosticator of worse OS (HR 2.01, 95% CI 1.22–3.56, p = 0.007) but not PFS. PLR ≥ 300 was also significantly associated with decreased OS (9.38 vs. 15.72 months, p = 0.007) and PFS (3.45 vs. 7.11 months, p = 0.04) compared to PLR < 300, but it was not an independent prognosticator of OS or PFS. NLR and PLR were not associated with objective response or disease control rates. NLR ≥ 5 independently prognosticated worse survival outcomes and is worthy of further study and validation
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Cancers. - 14, 23 (2022) , 5834, ISSN: 2072-6694
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2022
- Urheber
- DOI
-
10.3390/cancers14235834
- URN
-
urn:nbn:de:bsz:25-freidok-2322678
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:54 MEZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wu, Yue Linda
- Bettinger, Dominik
- Ang, Celina
- Universität
Entstanden
- 2022
Ähnliche Objekte (12)
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio in Univentricular Patients From Birth to Follow-Up After Fontan—Predicting Lymphatic Abnormalities
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Neutrophil-to-lymphocyte ratio and its association with critical limb ischemia in PAOD patients
Lymphocyte pathway analysis using naturally lymphocyte‐deficient fish
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
HCC-Biomarker in der Diagnostik und Therapie des Hepatozellulären Karzinoms (HCC) in verschiedenen Phasen der Erkrankung
The prognostic value of neutrophil-to-lymphocyte ratio in cholangiocarcinoma : a systematic review and meta-analysis
Neutrophil-to-Lymphocyte Ratio Is an Independent Predictor for In-Hospital Mortality in Spontaneous Intracerebral Hemorrhage
Neutrophil-to-lymphocyte ratio is associated with increased cerebral blood flow velocity in acute bacterial meningitis
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Lymphocyte activation : 8 tables
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio in Univentricular Patients From Birth to Follow-Up After Fontan—Predicting Lymphatic Abnormalities
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Neutrophil-to-lymphocyte ratio and its association with critical limb ischemia in PAOD patients
Lymphocyte pathway analysis using naturally lymphocyte‐deficient fish
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
HCC-Biomarker in der Diagnostik und Therapie des Hepatozellulären Karzinoms (HCC) in verschiedenen Phasen der Erkrankung
The prognostic value of neutrophil-to-lymphocyte ratio in cholangiocarcinoma : a systematic review and meta-analysis
Neutrophil-to-Lymphocyte Ratio Is an Independent Predictor for In-Hospital Mortality in Spontaneous Intracerebral Hemorrhage
Neutrophil-to-lymphocyte ratio is associated with increased cerebral blood flow velocity in acute bacterial meningitis
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Lymphocyte activation : 8 tables
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio in Univentricular Patients From Birth to Follow-Up After Fontan—Predicting Lymphatic Abnormalities
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Neutrophil-to-lymphocyte ratio and its association with critical limb ischemia in PAOD patients
Lymphocyte pathway analysis using naturally lymphocyte‐deficient fish
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
HCC-Biomarker in der Diagnostik und Therapie des Hepatozellulären Karzinoms (HCC) in verschiedenen Phasen der Erkrankung
The prognostic value of neutrophil-to-lymphocyte ratio in cholangiocarcinoma : a systematic review and meta-analysis
Neutrophil-to-Lymphocyte Ratio Is an Independent Predictor for In-Hospital Mortality in Spontaneous Intracerebral Hemorrhage
Neutrophil-to-lymphocyte ratio is associated with increased cerebral blood flow velocity in acute bacterial meningitis
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study